MDNAF News and Press, Mandatum Pankki Oyj From 10/17/19

Medicenna Announces Closing of Public Offering of $6,900,000 Canada NewsWire TORONTO and HOUSTON, Oct. 17, 2019 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , Oct. 17, 2019 /CNW/ - Medicenna Ther...

Medicenna Announces Filing of Final Short Form Prospectus Canada NewsWire TORONTO and HOUSTON, Oct. 11, 2019 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , Oct. 11, 2019 /CNW/ - Medicenna Therap...

Medicenna Announces Pricing of Marketed Offering of Units Canada NewsWire TORONTO and HOUSTON, Oct. 2, 2019 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , Oct. 2, 2019 /CNW/ - Medicenna Therapeut...

Medicenna Announces Offering of Units Canada NewsWire TORONTO and HOUSTON, Oct. 1, 2019 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON , Oct. 1, 2019 /CNW/ - Medicenna Therapeutics Corp. (" Me...

Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference Canada NewsWire TORONTO, Sept. 30, 2019 Results show superiority and desired differentiation from competing IL-2 programs ...

Long-acting and Tumor Targeting MDNA109 Variants Dramatically Improve T-cell Stimulation, Tumor Control and Long Term Memory Response TORONTO , Sept. 26, 2019 /PRNewswire/ -   Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a cli...

- Patients treated at the high dose show impressive survival benefit- -IL4R population surviving twice as long as current approved treatments- TORONTO and HOUSTON , Sept 25, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, O...

Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes Canada NewsWire TORONTO and HOUSTON, Sept. 24, 2019 Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON , Sept. 24, 2019 /CNW/ - Medicenn...

TORONTO and HOUSTON , Sept. 17, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present an update on the lead candidate from its IL-2 superkin...

TORONTO and HOUSTON , Sept. 12, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present updated clinical results from the Phase 2b clinical trial...